Oncolytic virotherapy improves immunotherapies targeting cancer stemness in glioblastoma
M Keshavarz, H Dianat-Moghadam… - Biochimica et Biophysica …, 2024
Despite advances in cancer therapies, glioblastoma (GBM) remains the most
resistant and recurrent tumor in the central nervous system. GBM tumor
microenvironment (TME) is a highly dynamic landscape consistent with alteration in
tumor infiltration cells, playing a critical role in tumor progression and invasion. In
addition, glioma stem cells (GSCs) with self-renewal capability promote tumor
recurrence and induce therapy resistance, which all have complicated eradication of …
resistant and recurrent tumor in the central nervous system. GBM tumor
microenvironment (TME) is a highly dynamic landscape consistent with alteration in
tumor infiltration cells, playing a critical role in tumor progression and invasion. In
addition, glioma stem cells (GSCs) with self-renewal capability promote tumor
recurrence and induce therapy resistance, which all have complicated eradication of …
| • | 引用: Efficacy of cancer-specific anti-podoplanin CAR-T cells and …  |
 |
 |
 |
 |
[PDF] The Impact of Glycosylation on the Functional Activity of CD133 and the Accuracy of Its Immunodetection
A Gisina, K Yarygin, A Lupatov - Biology, 2024
The membrane glycoprotein CD133 (prominin-1) is widely regarded as the main
molecular marker of cancer stem cells, which are the most malignant cell
subpopulation within the tumor, responsible for tumor growth and metastasis. For this
reason, CD133 is considered a promising prognostic biomarker and molecular target
for antitumor therapy. Under normal conditions, CD133 is present on the cell
membrane in glycosylated form. However, in malignancies, altered glycosylation …
molecular marker of cancer stem cells, which are the most malignant cell
subpopulation within the tumor, responsible for tumor growth and metastasis. For this
reason, CD133 is considered a promising prognostic biomarker and molecular target
for antitumor therapy. Under normal conditions, CD133 is present on the cell
membrane in glycosylated form. However, in malignancies, altered glycosylation …
| • | 引用: Establishment of CMab-43, a sensitive and specific anti-CD133  |